Updated November 7, 2026 | v7.4

Renal updates by clinical finding

Search 237 product updates by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.

Search all 1,215 records | Source cautions

Monitoring or toxicity

Insulin aspart (Fiasp), injection; verify presentation and route

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response.
Limits and monitoring: Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 18, posted Jul 25, 2023 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Insulin aspart (NovoLog), injection; verify presentation and route

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response.
Limits and monitoring: Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 34, posted Jan 22, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Insulin detemir (Levemir), subcutaneous injection

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response.
Limits and monitoring: Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 24, posted Oct 10, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Insulin glargine (Lantus), 100 units/mL subcutaneous injection

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response.
Limits and monitoring: Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 35, posted Jul 02, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Insulin glargine (Toujeo), 300 units/mL subcutaneous injection

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response.
Limits and monitoring: Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 25, posted Jun 12, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Insulin lispro (Humalog), injection; verify concentration and route

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response.
Limits and monitoring: Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 87, posted Aug 10, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Insulin lispro-aabc (Lyumjev), injection; verify concentration and route

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Reduced kidney function can change insulin requirements. Monitor glucose more often and titrate to the measured response.
Limits and monitoring: Confirm insulin identity, concentration and delivery device. The cited renal guidance gives no fixed percentage reduction.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 12, posted Aug 10, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Mesalamine (Apriso), oral extended-release capsule

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter.
Limits and monitoring: Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 36, posted Oct 22, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Mesalamine (Canasa), rectal suppository

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter.
Limits and monitoring: Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 32, posted Oct 26, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Mesalamine (Delzicol), oral delayed-release capsule

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter.
Limits and monitoring: Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.

Review 1 product or source caution

Verify the current prescribing information for this presentation.

DailyMed SPL version 3, posted Aug 08, 2016 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Mesalamine (Lialda), oral delayed-release tablet

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter.
Limits and monitoring: Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 50, posted Oct 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

Monitoring or toxicity

Mesalamine (Pentasa), oral extended-release capsules

Renal measure: Renal impairment categories as defined by the cited product label
Renal action or finding: Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter.
Limits and monitoring: Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 43, posted Oct 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Open evidence and renal guidance Prescribing information

RX coverage and remaining workload | Previous 90-product roundup